CDT · CDT Equity Inc. Common Stock
View on chartInsiders & Stakes
| Nirland Ltd 10% Owner | ▼ Sell | Open Market | 6,092,000 Shares held | 10/7/2024 | View profile |
| Regan Andrew Chief Executive Officer | ▼ Sell | Open Market | 5,692,933 Shares held | 8/28/2026 | View profile |
| Heilbron Jack Kendrick Chief Executive Officer | ▼ Sell | Other | 4,015,250 Shares held | 9/22/2023 | View profile |
| Bligh James Interim CFO | ▲ Buy | Grant | 480,024 Shares held | 9/19/2025 | View profile |
| Faith L. Charles Director | ▲ Buy | Grant | 165,238 Shares held | 4/16/2025 | View profile |
| Lewis-Hall Freda C Director | ▲ Buy | Grant | 38,466 Shares held | 8/12/2025 | View profile |
| Fry Simon Jeremy Director | ▲ Buy | Grant | 36,956 Shares held | 8/12/2025 | View profile |
| Farley Chele Chiavacci Director | ▲ Buy | Grant | 17,157 Shares held | 2/19/2026 | View profile |
| Adam Sragovicz Chief Financial Officer | ▼ Sell | Other | 0 Shares held | 5/15/2024 | View profile |
| Taylor Mark Andrew 10% Owner | ▼ Sell | Open Market | 0 Shares held | 6/18/2026 | View profile |
Transaction History
| Regan Andrew | ▼ Sell | Other | 5,436,830 | — | 8/28/2026 |
| Regan Andrew | ▼ Sell | Open Market | 290 | — | 8/28/2026 |
| Taylor Mark Andrew | ▼ Sell | Open Market | 5,000 | $4K | 6/18/2026 |
| Taylor Mark Andrew | ▼ Sell | Open Market | 1,464,711 | $2.1M | 6/18/2026 |
| Taylor Mark Andrew | ▼ Sell | Open Market | 5,000 | $4K | 6/18/2026 |
| Taylor Mark Andrew | ▼ Sell | Open Market | 593,289 | $829K | 6/18/2026 |
| Regan Andrew | ▲ Buy | Grant | 100,000 | $190K | 5/13/2026 |
| Regan Andrew | ▲ Buy | Grant | 147,401 | — | 3/24/2026 |
| Taylor Mark Andrew | ▼ Sell | Other | 51,420,358 | $0 | 3/17/2026 |
| Farley Chele Chiavacci | ▲ Buy | Grant | 10,553 | $11K | 2/19/2026 |
| Taylor Mark Andrew | ▼ Sell | Other | 46,902 | $0 | 2/19/2026 |
| Regan Andrew | ▲ Buy | Grant | 224,800 | $402K | 12/8/2025 |
| Bligh James | ▲ Buy | Grant | 480,000 | $0 | 9/19/2025 |
| Regan Andrew | ▲ Buy | Grant | 1,120,000 | $769K | 9/19/2025 |
| Farley Chele Chiavacci | ▲ Buy | Grant | 35,000 | $0 | 8/12/2025 |
| Fry Simon Jeremy | ▲ Buy | Grant | 35,000 | $0 | 8/12/2025 |
| Lewis-Hall Freda C | ▲ Buy | Grant | 35,000 | $0 | 8/12/2025 |
| Regan Andrew | ▲ Buy | Grant | 154,799 | $500K | 6/3/2025 |
| Faith L. Charles | ▲ Buy | Grant | 115,194 | $100K | 4/16/2025 |
| Lewis-Hall Freda C | ▲ Buy | Grant | 47,612 | $42K | 3/30/2025 |
| Fry Simon Jeremy | ▲ Buy | Grant | 29,354 | $26K | 3/30/2025 |
| Faith L. Charles | ▲ Buy | Grant | 46,629 | $41K | 3/30/2025 |
| Farley Chele Chiavacci | ▲ Buy | Grant | 32,022 | $28K | 3/30/2025 |
| Lewis-Hall Freda C | ▲ Buy | Grant | 437,976 | $40K | 11/18/2024 |
| Farley Chele Chiavacci | ▲ Buy | Grant | 299,238 | $27K | 11/18/2024 |
| Faith L. Charles | ▲ Buy | Grant | 266,594 | $24K | 11/18/2024 |
| Faith L. Charles | ▲ Buy | Grant | 75,000 | — | 11/18/2024 |
| Nirland Ltd | ▼ Sell | Open Market | 939,009 | $97K | 10/7/2024 |
| Nirland Ltd | ▼ Sell | Open Market | 1,368,991 | $140K | 10/4/2024 |
| Nirland Ltd | ▼ Sell | Open Market | 1,500,000 | $156K | 10/3/2024 |
| Nirland Ltd | ▼ Sell | Open Market | 333,177 | $34K | 10/2/2024 |
| Nirland Ltd | ▼ Sell | Open Market | 1,250,000 | $141K | 10/1/2024 |
| Nirland Ltd | ▼ Sell | Open Market | 1,016,823 | $122K | 9/30/2024 |
| Regan Andrew | ▼ Sell | Open Market | 1,514,100 | $391K | 7/17/2024 |
| Regan Andrew | ▼ Sell | Open Market | 10,244,392 | $3.2M | 7/16/2024 |
| Regan Andrew | ▼ Sell | Open Market | 1,005,200 | $248K | 7/15/2024 |
| Regan Andrew | ▼ Sell | Open Market | 1,389,820 | $343K | 7/12/2024 |
| Regan Andrew | ▼ Sell | Open Market | 582,952 | $173K | 7/11/2024 |
| Regan Andrew | ▼ Sell | Open Market | 300,000 | $87K | 7/11/2024 |
| Regan Andrew | ▼ Sell | Open Market | 150,000 | $50K | 7/10/2024 |
| Regan Andrew | ▼ Sell | Open Market | 77,681 | $34K | 7/9/2024 |
| Regan Andrew | ▼ Sell | Open Market | 35,923 | $18K | 7/8/2024 |
| Regan Andrew | ▼ Sell | Open Market | 1,000 | $640 | 7/3/2024 |
| Regan Andrew | ▼ Sell | Other | 1,100,000 | — | 6/14/2024 |
| Regan Andrew | ▼ Sell | Other | 1,100,000 | — | 6/14/2024 |
| Bligh James | ▲ Buy | Grant | 37,272 | — | 6/11/2024 |
| Farley Chele Chiavacci | ▲ Buy | Grant | 37,272 | — | 6/11/2024 |
| Adam Sragovicz | ▼ Sell | Other | 74,545 | $0 | 5/15/2024 |
| Adam Sragovicz | ▲ Buy | Grant | 74,545 | — | 12/1/2023 |
| Heilbron Jack Kendrick | ▲ Buy | Option Exercise | 4,060,250 | $0 | 9/22/2023 |
| Heilbron Jack Kendrick | ▼ Sell | Other | 45,000 | $0 | 9/22/2023 |
| Farley Chele Chiavacci | ▲ Buy | Grant | 15,000 | — | 9/22/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
CDT Highlights Sarborg Quantum Computing IP for Drug Discovery
CDT announced that it is focusing on Sarborg's expanding quantum computing intellectual property and its application to drug discovery. The company was also mentioned among health‑care stocks that moved in Friday's session, showing recent market attention. The stock is currently near a long‑standing support level, which may be observed as the company pursues these initiatives.
CDT Highlights Sarborg Quantum Computing IP for Drug Discovery. CDT announced that it is focusing on Sarborg's expanding quantum computing intellectual property and its application to drug discovery. The company was also mentioned among health‑care stocks that moved in Friday's session, showing recent market attention. The stock is currently near a long‑standing support level, which may be observed as the company pursues these initiatives.